PRINCETON, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the ...
Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial ...
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer ...
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the ...
Clinical Trials Arena on MSN
PDS Biotech’s stock up on colorectal cancer trial success
PDS Biotech has released data from the Phase II investigator-led colorectal cancer trial.
DALLAS — A PDS Severe Thunderstorm Watch is in effect across North Texas Sunday night into early Monday morning. A PDS Severe Thunderstorm Watch is a type of alert indicating that the threat of damage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results